Clinical Trials Browser

Phase 2 × Lymphoma, Non-Hodgkin × Nivolumab × Clear all

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms

NCT03297606 2026-03-27

CAPTUR

Phase 2 Recruiting

720 enrolled

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma

NCT04205409 2025-11-03

Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies

Phase 2 Active not recruiting

20 enrolled 12 charts

LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT01703949 2025-06-11

Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ Lymphoma

Phase 2 Active not recruiting

28 enrolled

Lymphoid

Hodgkin Disease, Lymphoma, Non-Hodgkin

NCT03620578 2024-02-14

HO152

Phase 2 Active not recruiting

97 enrolled

Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

NCT02038933 2021-10-14

Study of Nivolumab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) That Have Either Failed or Are Not Eligible for Autologous Stem Cell Transplant (CheckMate 139)

Phase 2 Completed

121 enrolled 16 charts

Lymphoid

Lymphoma, Non-Hodgkin

Clinical Trials

TAPUR

CAPTUR

Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies

Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ Lymphoma

HO152

Study of Nivolumab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) That Have Either Failed or Are Not Eligible for Autologous Stem Cell Transplant (CheckMate 139)